Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2024.06.033 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Timothy K Nguyen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Oncology, Western University and London Health Sciences Centre, London, Ontario, Canada. Hauptthemen laut MEDLINE: Radiosurgery, Quality of Life, Feasibility Studies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: London Health Sciences Foundation.
Abstract (Originalsprache)
PURPOSE: This phase 1 study aimed to assess the safety and feasibility of SABR therapy delivery to all sites of polymetastatic disease (>10 metastases). METHODS AND MATERIALS: A 3 + 3 study design was used with 5 dose levels from 6 Gy (6 Gy × 1) to 30 Gy (6 Gy weekly × 5). Dose-limiting toxicity (DLT) was defined as any grade 4 or 5 toxicity or more than 3 grade 3 toxicities within 6 weeks of treatment. The primary endpoint was the maximal tolerated dose, defined as the dose level where ≥2/6 of patients experienced DLT. Secondary endpoints included quality of life (Functional Assessment of Cancer Therapy - General and European Quality of Life 5 Dimension 5 Level) at 6 weeks posttreatment, progression-free survival, and overall survival. RESULTS: Thirteen patients were accrued: 12 Gy (n = 3), 18 Gy (n = 3), 24 Gy (n = 4), and 30 Gy (n = 3), and 207 lesions were treated. Nine patients (69%) had acute toxicity: grade 1 (n = 6, 46%), grade 2 (n = 2, 15%; n = 1 pneumonitis and n = 1 fatigue), and grade 3 (n = 1, 7.7% neutropenia). There were no grade 4 or 5 toxicities. Mean ± SD quality of life (Functional Assessment of Cancer Therapy - General and European Quality of Life 5 Dimension 5 Level health state) was 80.4 ± 21.9 and 77.4 ± 20.9 at baseline versus 76.4 ± 21.8 and 68.0 ± 24.2 at 6-week follow-up, respectively (p = .009 and p = .055, respectively). With a median follow-up of 8.7 months posttreatment (IQR, 2.4-24 months), 8 of 13 patients had disease progression (62%). The median and 12-month progression-free survival were 3.6 months and 11.3%, respectively. The median and 12-month overall survival were 13.8 months and 62%, respectively. CONCLUSIONS: In this phase 1 trial, SABR therapy for polymetastatic disease was technically feasible with acceptable acute toxicity at dose levels up to 30 Gy (6 Gy weekly × 5). DLT was not observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Radiation Oncology, Department of Oncology, Western University and London Health Sciences Centre, London, Ontario, Canada.
- Division of Radiation Oncology, Department of Radiology, The Ottawa Hospital, Ottawa, Ontario, Canada.
- Department of Medical Biophysics, Western University, London, Ontario, Canada.
- Department of Radiation Oncology, Niagara Health, St. Catherine's, Ontario, Canada.
- Division of Radiation Oncology, Department of Oncology, Western University and London Health Sciences Centre, London, Ontario, Canada. Electronic address: Glenn.Bauman@lhsc.on.ca.
Förderung
- London Health Sciences Foundation
Zitieren
APA
Nguyen, T. K., Ramadan, S., Palma, D. A., Corkum, M. T., O' Neil, M., Celinski, A., Fakir, H., Warner, A., Hallock, A., Correa, R. J. M., Qu, X. M., Lock, M., Lang, P., Velker, V., & Bauman, G. S. (2024). Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.06.033
Vancouver
Nguyen TK, Ramadan S, Palma DA, Corkum MT, O' Neil M, Celinski A, et al. Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.06.033
BibTeX
@article{Nguyen2024,
author = {Nguyen, Timothy K and Ramadan, Sherif and Palma, David A and Corkum, Mark T and O' Neil, Melissa and Celinski, Anders and Fakir, Hatim and Warner, Andrew and Hallock, Abhirami and Correa, Rohann J M and Qu, X Melody and Lock, Michael and Lang, Pencilla and Velker, Vikram and Bauman, Glenn S},
title = {Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2024.06.033}
}
EUVIMED